The primary purpose of Relvar Ellipta is to provide daily, long-term therapeutic support, applied across therapeutic domains involving chronic symptoms related to airway narrowing and irritative states. It is a maintenance medication, not an emergency treatment.

This medicine is commonly used for the regular, long-term treatment of Asthma in adults and adolescents 12 years and older, and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. This medicine is relevant for managing conditions involving episodic or fluctuating manifestations and symptoms that create noticeable physiological strain.

The medication plays a role in managing symptoms that become more disruptive during flare-ups and may assist with reducing the likelihood of severe symptoms. The long-acting nature of the medicine supports sustained opening of the breathing passages. This sustained effect assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations across the entire day.

---

Quick Fact: Symptom Categories Addressed The therapy is primarily focused on easing symptoms related to physical discomfort such as wheezing, chronic shortness of breath, and chest tightness, while also supporting a reduction in the overall symptom burden associated with chronic airway inflammation.

Regulatory References

1. European Medicines Agency overview

Who can and cannot use Relvar Ellipta?

This medication is authorized for the maintenance treatment of certain respiratory conditions and is subject to strict eligibility rules defined in regulatory documents.

Populations for Whom Use is Allowed

• Asthma: Adults and adolescents aged 12 years and older.
• COPD (Chronic Obstructive Pulmonary Disease): Adults aged 18 years and older.

Populations for Whom Use is Contraindicated

Use of this medicine is absolutely prohibited in the following groups:

• Patients with a documented history of severe hypersensitivity or allergy to fluticasone furoate, vilanterol, or any of the excipients, including severe allergy to milk proteins.
• Patients who are concurrently receiving any other medication that contains a Long-Acting beta2-Agonist (LABA).
• It must not be used for the relief of acute bronchospasm or acutely worsening asthma/COPD symptoms.

Eligibility-Related Restrictions

• Age: The safety and efficacy in children under 12 years of age for asthma, and in all children and adolescents under 18 years for COPD, have not been established, and use is not authorized.
• Hepatic Impairment: For patients with moderate or severe liver impairment, the maximum authorized dose is restricted to the lower strength (92/22 micrograms or 100/25 micrograms, depending on region), and patients should be closely monitored.

Relvar Ellipta (fluticasone furoate/vilanterol) contains two active substances that are susceptible to specific drug interactions documented in official regulatory labeling.

Interactions with Other Medicines

Category/Product	Mechanistic Basis & Classification	Consequence and Constraint
Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, cobicistat)	CYP3A4 enzyme inhibition, leading to decreased clearance of fluticasone furoate and vilanterol. Use with caution.	Increased systemic exposure to both components, raising the potential risk of corticosteroid side effects (like adrenal suppression) and sympathomimetic adverse effects.
Other Long-Acting Beta2-Agonists (LABA) (e.g., salmeterol, formoterol)	Additive sympathomimetic effects. Do not use in combination.	Significantly increased risk of cardiovascular adverse events and overdose. Patients must not use another medicine containing a LABA for any reason.
Non-Selective Beta-Blockers	Pharmacodynamic antagonism. Use with caution.	Potential for reduced bronchodilator effect of vilanterol and risk of severe bronchospasm.
Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs)	Potentiation of vilanterol's effect on the vascular system. Use with extreme caution.	Increased risk of cardiovascular adverse events.
Non–Potassium-Sparing Diuretics	Additive effects on electrolytes. Use with caution.	Worsening of electrocardiographic changes and/or hypokalemia (low potassium) associated with beta-agonists.

It is essential to consult with a healthcare professional to review all concurrent medications and products, including those used for acute symptoms, to ensure safety and prevent serious drug interactions.

Sustained Agonism of the Beta-2 Adrenergic Receptor

The Vilanterol component acts as a selective agonist on the β2-Adrenergic Receptor (β2-AR), a G-protein coupled receptor. This interaction rapidly elevates intracellular cyclic AMP (cAMP), initiating a molecular cascade that relaxes the bronchial smooth muscle cells. The drug’s structure facilitates ultra-long β2-AR residence time, prolonging receptor stimulation and the resulting physiological bronchodilation for approximately 24 hours.

Glucocorticoid Receptor-Mediated Transcriptional Control

Fluticasone Furoate binds to the cytosolic Glucocorticoid Receptor (GR), and the complex translocates to the nucleus to perform two genomic actions: transrepression of pro-inflammatory transcription factors like NF-κB and transactivation of anti-inflammatory genes. This mechanism suppresses inflammatory signaling, leading to a reduction in tissue edema and inflammatory mediator production within the airways.

Mechanistic Synergy for Airway Stabilization

The mechanism involves the coordinated action and functional synergy between the two active ingredients. The β2-AR agonism provides rapid, sustained muscular relaxation, while the GR agonism addresses the underlying biological drivers of chronic inflammation. This dual approach facilitates the modulation of both immunological activity and continuous regulation of smooth muscle tone, influencing the two distinct pathological processes concurrently.

Official Administration Guidelines

Relvar Ellipta (fluticasone furoate/vilanterol) is a dry powder for inhalation (DPI) and must be administered exclusively via the oral inhalation route using the Ellipta inhaler device. It is prescribed for long-term daily maintenance and is not indicated for the immediate relief of acute breathing difficulties or sudden attacks.

---

Dosing and Schedule

Indication	Recommended Dosage (Once Daily)	Strength Constraint
COPD (Adults ge 18)	One inhalation of the 100/25 mcg or 92/22 mcg strength	Higher 200/25 mcg (184/22 mcg) strength is not approved for COPD.
Asthma (Adults ge 18)	Starting dose is 100/25 mcg (92/22 mcg). Can increase to 200/25 mcg (184/22 mcg).	The 200/25 mcg (184/22 mcg) strength is the maximum recommended dose.

All doses must be administered once daily at the same time every day. The choice of morning or evening administration is determined by the prescriber. Administration should not exceed one inhalation every 24 hours.

---

Special Use Instructions

Following each dose, the patient is explicitly instructed to rinse their mouth with water and spit it out without swallowing to help mitigate local residue. This is a mandatory procedural step.

In the event of a missed dose, the next scheduled dose should be taken at the usual time the following day; a patient must never take two doses on the same day to make up for the missed one. No dose adjustment is required for geriatric patients or those with renal impairment. However, for patients with moderate to severe hepatic impairment, the maximum dose is the lower strength (100/25 mcg or 92/22 mcg).

Research evidence / Overview of studies for Relvar Ellipta

Evidence for use in Asthma Maintenance Treatment

This section will summarize the types of Randomized Controlled Trials (RCTs) and real-world studies that were conducted, focusing on the outcomes measured, such as lung function changes and exacerbation frequency in adults and adolescents with persistent asthma.

Relvar Ellipta was evaluated in research exploring its potential use in long-term maintenance therapy for adults and adolescents (generally age 12 and older) whose asthma was not adequately controlled on their previous inhaled corticosteroid (ICS) therapy. Research examined the medicine for use in asthma, a condition where symptoms may vary in intensity. The main studies included a blend of controlled trials, which compared the combination against an inactive placebo, against the individual components alone, and against other existing combination therapies. Research explored outcomes including changes in lung function, especially measures like FEV1, which reflect how much air can be exhaled. Additionally, trials explored patient-reported outcomes describing perceived discomfort and the frequency of severe asthma flare-ups (exacerbations).

Studies exploring short-term symptom changes reported measurements of lung function in various groups when the combination was evaluated against the placebo or the inhaled corticosteroid component used alone. Research also explored patterns in patient-reported outcomes describing perceived discomfort. Furthermore, real-world randomized studies in everyday clinical practice settings also conducted research on this medicine, and data show patterns related to asthma control. These findings describe patterns observed in the studies over defined time intervals, typically lasting 6 to 12 months.

Research on Symptom Control and Lung Function

This subsection describes how studies used standardized patient questionnaires and objective measures like FEV1 to evaluate the medicine's performance against placebo and its individual components.

Controlled trials applied in studies examining patient-reported experiences used standardized questionnaires to track changes in patient comfort and outcomes related to physical discomfort. Research also examined the consistency of lung function readings over defined time intervals. When the combination was evaluated in trials against its individual components alone, findings reflected patterns in lung function measurements.

Real-World Evidence and Comparator Trials

This subsection outlines the structure and findings of large-scale observational studies and trials that compared the combination's use against a patient's usual, pre-existing care regimen.

Evidence derived from settings with varying symptom burdens explored patterns related to symptom control and exacerbation frequency. These studies compared the combination against other established care approaches. However, since the comparator group in these real-world studies used many different medicines, comparative evidence is lacking against every similar combination product.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

This section outlines the structure of the clinical research program for COPD, including the event-driven studies and observational research that examined outcomes like the rate of COPD flare-ups and patient-reported health status.

For the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD), research explored the combination in conditions marked by functional limitations and often a history of acute episodes. The clinical program included long-term, event-driven RCTs which lasted up to one year or more. This type of research was evaluated in tracking the occurrence of moderate or severe COPD exacerbations, which are outcomes describing episodic or acute changes. The studies monitored the medicine against placebo, the individual components, and other existing treatments.

Focus on Exacerbation Event Studies

This subsection details the design of long-term studies specifically created to track and measure the occurrence and severity of COPD flare-ups as a primary research outcome.

The event-driven research was evaluated in adult populations (typically age 40 and older) with moderate to severe airflow limitation. These long-term studies focused on outcomes capturing phases of heightened symptom activity that require systemic treatment or hospitalization. Trials comparing the combination to placebo monitored differences in exacerbation rates between the groups.

Functional Measures in COPD

This subsection summarizes how research assessed objective functional measures and patient health status scores within the specific populations studied.

Research examined changes in FEV1 to monitor physiological strain. In addition to these objective measures, studies used specialized questionnaires to assess patient-reported outcomes describing perceived discomfort and overall health-related quality of life. Findings described patterns of change in these patient-reported scores when the combination was evaluated in comparison to its individual components and placebo.

---

Long-Term Studies and Follow-Up

This section will describe the typical duration of the key clinical trials and post-marketing surveillance, outlining the extent of data available regarding the durability of findings and the monitoring of sustained use over periods greater than one year.

The pivotal research for both asthma and COPD generally included follow-up durations of at least six months, with many large studies extending up to one year. This established a defined period of observed use for which evidence is available. However, while post-marketing surveillance is ongoing, long-term outcomes are not fully established beyond the trial window, and data are still emerging from ongoing research.

Evidence in Special Populations

This section will detail the availability and scope of research concerning specific patient groups, such as adolescents, older adults, or any cohorts defined by disease severity or the presence of other chronic conditions where evidence was specifically collected.

The main body of evidence applies only to the populations studied, which includes adults and adolescents ge 12 years for asthma and adults ge 40 years for COPD. Data for certain groups remain insufficient, particularly for children under the age of 12 years. Also, certain large trials included analysis of specific respiratory events in the COPD population, an observation that was noted in some studies.

What is Still Uncertain About the Research

This section will clearly and neutrally identify known research gaps, which include areas with limited or inconsistent data, such as evidence in younger children or definitive head-to-head comparisons against all similar combination therapies.

The long-term outcomes are not fully established beyond the one-year mark of the primary trials, and research is ongoing to track these outcomes. Comparative evidence is lacking for certain head-to-head comparisons against other specific ICS/LABA products used in clinical practice. Finally, subgroup findings are uncertain in some instances, and the evidence quality varies across studies, leading to complexity when synthesizing the broader evidence landscape.

Common questions about Relvar Ellipta (FAQ)

Q: Does Relvar Ellipta treat asthma attacks or COPD flare-ups?

A: According to official product information, Relvar Ellipta is a maintenance medicine used to prevent symptoms over time. It is not a 'rescue' inhaler and should not be used to treat sudden, severe asthma attacks or COPD flare-ups that require immediate relief. A separate rapid-acting inhaler is intended for these acute situations.

Q: Can I use Relvar Ellipta only when I feel symptoms coming on?

A: Regulatory documents state that Relvar Ellipta is designed for use every day, on a regular schedule, even when a patient feels well. This consistent use supports the medicine's long-term goal of preventing symptoms. Stopping or changing the prescribed regimen could potentially affect the stability of long-term symptom control, according to official guidance.

Q: How long does it take for Relvar Ellipta to start working for my condition?

A: Official information indicates that Relvar Ellipta is a medicine for long-term control. While some effects may be felt quickly, the full therapeutic benefit in improving lung function and managing symptoms develops gradually. The maximum effect is typically established over several weeks of regular, daily use.

Q: What should I do if I miss a dose of Relvar Ellipta?

A: Official guidance usually describes specific steps for a missed dose, such as taking it as soon as it is remembered, unless it is almost time for the next scheduled dose. If that is the case, the missed dose is typically skipped. Regulatory documents advise that two doses should generally not be taken at the same time to compensate for a missed dose.

Q: Can I stop using Relvar Ellipta if my symptoms go away?

A: Studies and official information advise against stopping the use of maintenance medicine like Relvar Ellipta suddenly, even when breathing symptoms appear well controlled. Stopping treatment without planning may cause symptoms to worsen or return. Official prescribing information stresses that changes to the daily maintenance treatment should be made only in consultation with a healthcare provider.

Q: What is the age limit for using Relvar Ellipta for asthma?

A: According to the official product information for asthma treatment, Relvar Ellipta is intended for use in adult patients and adolescents. The regulatory minimum age specified for starting this treatment is 12 years and older.

Q: What is the age limit for using Relvar Ellipta for COPD?

A: The official product information for chronic obstructive pulmonary disease (COPD) treatment indicates that Relvar Ellipta is approved for use only in adults. It is not generally intended for patients under the age of 18 for this specific condition.

Storage Conditions

Relvar Ellipta must be stored strictly according to the conditions defined in the official prescribing information to protect the dry powder formulation. The inhaler must be kept in its original sealed foil tray until ready for first use to protect it from moisture. Storage should be at room temperature; the medicine must not be frozen.

Stability and Child Safety

Once the foil tray is opened, the inhaler must be discarded after 6 weeks, or when the dose counter reaches zero, whichever comes first. The product must be stored out of the sight and reach of children.

Disposal

The disposal of unused product and waste material must be carried out in accordance with local regulatory requirements.